EP3897604A1 - Topical compositions - Google Patents
Topical compositionsInfo
- Publication number
- EP3897604A1 EP3897604A1 EP19898484.1A EP19898484A EP3897604A1 EP 3897604 A1 EP3897604 A1 EP 3897604A1 EP 19898484 A EP19898484 A EP 19898484A EP 3897604 A1 EP3897604 A1 EP 3897604A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- acid
- weight
- composition
- carbon atoms
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
Definitions
- the present invention relates to topical compositions for skin tissue including nails and, in particular, to liquid carriers/vehicles for pharmacologically active components forming the topical coposition.
- compositions for topical application to the skin heavily rely on the penetrating ability of the composition for maximum efficacy.
- treatments of fungal infections of the toe nail, or toe nail discoloration due to other underlying factors are largely dependent on the ability of the active agent, an antifungal to penetrate the skin surrounding the nail as well as the nail itself.
- nails are actually produced by living skin cells in the toe or finger.
- ingredients used in cosmetic applications can hydrate, thin, and normalize the color of nails and skin. Rehydrating a fungal nail that is dehydrated and dried out can increase porosity of the cells in the nail matrix making it easier for penetration of agents needed to treat the nail, e.g., for fungus.
- Jublia® antifungal composition for the treatment of nail disorders such onychomycosis or psoriasis affecting the nails, a widely used prescription antifungal is sold under the trademark Jublia®.
- the composition of the Jublia® antifungal composition uses a vehicle in which the active ingredient is dissolved, which preferably comprises a linear or branched aliphatic lower alcohol, such as ethanol, methanol, propanol, or isopropanol.
- a linear or branched aliphatic lower alcohol such as ethanol, methanol, propanol, or isopropanol.
- U.S. Patent 10,05,444 (‘444 Patent), incorporated herein by reference for all purposes, covers the Jublia® antifungal composition.
- The‘444 Patent encompasses and is focused on the fact that the composition claimed therein meets a significant need for a pharmaceutical composition that provides for enhanced penetration of a pharmaceutical agent contained within the composition into, under, around, and through a nail into the nail bed.
- the composition of the‘444 Patent also relies on a surfactant to reduce surface tension and a volatile silicone to act as a wetting agent.
- the teachings of the‘444 Patent highlight the fact that penetration is quite important in successfully treating skin disorders, e.g., fungal infections, of the nails and surrounding tissue.
- the present invention relates to an antifungal composition for application to the toe nail and adjoining tissue.
- the present invention relates to a pharmaceutically active composition for the treatment of fungal infections on and surrounding the toe nail.
- the present invention relates to a composition
- a composition comprising a carrier and an effective amount of a pharmaceutically active antifungal component wherein the antifungal component is uniformly dispersible in a carrier.
- the present invention relates to a carrier or vehicle for use in the topical application of dermatologically active ingredients.
- the present invention relates to a carrier for use in topical application of dermatologically active ingredients which exhibits good penetrating ability.
- Fig. 1 shows the penetrating ability of the compositions of the present invention as compared to a widely used commercial prior art product.
- the terms“nail” or“nails” means one or more of the toe nails and/or finger nails of an animal, particularly humans.
- the present invention comprises a liquid carrier or vehicle for dermatologically active ingredients (DAIs), e.g., antifungals or cosmetic components, to form a dermatologically active composition (DAC).
- DAIs dermatologically active ingredients
- DAC dermatologically active composition
- the liquid carrier or vehicle comprising the present invention contains dimethyl isosorbide, undecylenic acid, a carboxylic acid component other than undecylenic acid, a monohydric alcohol having from 2 to 4 carbon atoms, and a urea based component.
- the carrier will contain:
- urea-based component is urea itself
- a suitable urea-based component can comprise urea peroxide or carbamide peroxide.
- Urea-based components act as nail penetrators and/or softeners. Further, these urea-based components serve a cosmetic function in that they improve the visual appearance of the nail by hydrating and thinning hyperkeratotic nails, thereby providing an incentive for the user to be diligent in applying the DAC.
- the carrier of the present invention comprises a monohydric alcohol containing 2 to 4 carbon atoms.
- the monohydric alcohol can be ethanol, propanol, isopropanol, etc., isopropanol being preferred.
- the carrier can contain up to about 7% water.
- the carrier of the present invention also contains a carboxylic acid component other than undecylenic acid.
- the carboxylic acid component comprises a C1 to C10 organic acid which can be alone and/or in an aqueous solution.
- C1 -C10 carboxylic acids suitable for use in the carrier of the present invention include saturated and/or unsaturated, linear and/or branched, aliphatic, mono-, di-, carboxylic acids, alkylaryl or aromatic dicarboxylic acids, oxy- and hydroxyl- carboxylic acids (e.g., alpha- hydroxy acids).
- Preferred carboxylic acids include formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, capyric acid, capric acid, sorbic acid, oxalic acid, hydroxybutyric acid, hydroxypropionic acids, lactic acid, glycolic acid, citric acid, malic acid, tartartic acid, malonic acid, fumaric acid, succinic acid, glutaric acid, apidic acid, pimelic acid, oxalacetic acid, phthalic acid, tartronic acid, pyruvic acid, and mixtures thereof.
- An especially preferred carboxylic acid is lactic acid.
- undecylenic acid (undec-10-enoic acid), an unsaturated fatty acid. While not wanting to be bound by any particular theory, it is believed undecylenic acid acts as a linking agent which brings certain components of the carrier together to enhance penetration. It is also believed that undecylenic acid can act as a biocide/antimicrobial to some extent and thereby enhance the stability of the carrier of the present invention. Further, when the carrier is used in forming a DAC employing an antifungal as the active ingredient, the undecylenic acid has the additional benefit that, in and of itself, in certain amounts it possesses antifungal properties thereby enhancing the efficacy of the DAC. Undecylenic acid also reduces the surface tension of and emulsifies other agents present in the carrier.
- DMI dimethyl isosorbide
- a useful component which can be used in the carrier of the present invention can also include a diol containing from about 2 to about 4 carbon atoms.
- suitable diols include ethylene glycol, propylene glycol, etc.
- a preferred diol is propylene glycol. If used, the diol will generally be present in an amount of from about 4 to about 15% by weight, preferably from about 4 to about 10% by weight.
- Another useful component which can be used in the carrier comprises about 10% by weight of a carboxylic acid ester having the formula:
- Ri comprises 1 to 3 carbon atoms
- R2 comprises 2 to 4 carbon atoms.
- Yet another useful component which may be used in the carrier comprises from about 2 to about 10% by weight of a fatty acid ester having the formula
- Ri comprises 1 to 3 carbon atoms
- R3 comprises 10 to 22 carbon atoms.
- adjunct components mentioned above i.e. , diols and esters, including the fatty acid esters, can be useful in certain applications to make the DACs more pleasing in smell and/or for ease in application. However, they are not considered to be critical components of the carrier and/or the DACs comprising the carrier.
- a feature of the carrier of the present invention is that a wide variety of DAI’s are dispersible in the carrier.
- the term “dispersible,” “dispersion,” or variants thereof is intended to mean and include a solution, an emulsion, a suspension, or a slurry to the extent the slurry can be formed into a uniform dispersion of particles / carrier with sufficient agitation and remain in that uniform state for a period of time sufficient for the carrier and its dispersed ingredient(s) to be uniformly applied to a skin surface, e.g., the nail and surrounding tissue.
- the carrier of the present invention is a liquid vehicle in which the DAI can be dissolved, suspended, dispersed, or emulsified.
- the DAC of the present invention may form a single phase, e.g., a solution, or separate phases, e.g., a slurry, emulsion, suspension, or the like.
- the slurry will be one which upon sufficient agitation can be formed into a uniform dispersion or suspension for a period of time to allow the DAC to be applied to the desired skin or nail area, the DAI being delivered to the affected skin area in a generally uniform fashion.
- the DAC of the present invention may be prepared in a number of forms including creams, milks, solutions, tinctures, liniments, liquids, sprays, suspensions, gels, or lotions.
- the carrier composition of the present invention can be used to “bleach” and/or remove discoloration from nails which may have been caused by several well known underlying diseases.
- the DAC from a cosmetic perspective, can be the carrier alone or have incorporated the DAIs such as skin softeners, emollients, etc.
- DAI comprising an antifungal
- antifungal any antifungal can be employed.
- the following well known, widely used antifungals for skin tissue, including nails includes, without limitation:
- -Azoles including efinaconazole, clotrimazole, miconazole nitrate, ketoconazole, econazole, bifonazole, oxiconazole, tioconazole, sertaconazole, luliconazole, eberconazole, sulconazole, fenticonazole, fluconazole, preferably efinaconazole, clotrimazole, or miconazole nitrate.
- -Allylamines including preferably, terbinafine, naftifine hydrochloride, butenafine hydrochloride,
- -Morpholines including preferably amorolfine hydrochloride
- Hydroxyquinolines including preferably clioquinol
- -Oxaboroles including preferably tavaborole
- -Thiocarbamates including preferably tolfnaftate
- the antifungal is selected from thiocarbamates, azoles, and allylamines, even more preferably tolnaftate, clotrimazole, and terbinafine, the most preferred antifungal being tolnaftate.
- antifungals when antifungals comprise the DAI, they will be present in an effective amount, wherein an effective amount means an amount necessary to affect a curative change in the fungus or other abnormality being treated. In this regard, it is well within the scope of the skilled artisan to determine what constitutes an effective amount.
- the literature is replete with compositions containing antifungals and the relative amounts used in such compositions. Accordingly, the skilled artisan would not have to engage in undue experimentation to determine what amount of antifungal should be used in the DACs of the present invention.
- the antifungals when the antifungals comprise the DAI, they will comprise from greater than 0 to about 15% by weight or greater of the DAC.
- the antifungal component was mixed with dimethyl isosorbide, forming
- Mixture A B) Urea, undecylenic acid, lactic acid, and IPA were mixed together forming Mixture B.
- compositions of the various DACs prepared are shown in Table 1.
- the penetration test was conducted using a substrate comprising polyurethane foam blocks marketed by Pacific Research Laboratories under the designation“Block 10 PCF” and commonly used for biomechanical testing.
- the faces of two blocks of the substrate were positioned between platens, the assembly of platens and substrate blocks being compressed together using the same and constant compression for each test..
- Each of the samples was dyed with fluorescein to improve visibility of the liquid.
- Two drops of each sample were applied at the top on the seam between the compressed substrate blocks.
- the samples were allowed to sit for 20 seconds, then the excess liquid was dabbed away.
- the samples were then allowed to dry for 2 minutes, after which the blocks were separated.
- the amount of penetration of the sample through the substrate was observed.
- Fig. 1 the borders of the penetration of the samples have been traced with a marker for ease of viewing.
- all of the compositions of the present invention penetrated further than the Jublia® composition.
- the carrier compositions of the present invention are effective at dispersing, as that term is defined above, a wide variety of antifungals from varied classes of antifungals, all of which are known to have antifungal activity.
- the DACs of the present invention wherein the DAIs are antifungals show better penetrating ability than the Jublia® formulation. This is significant, as noted above, since in the Jublia® composition in order to enhance penetration, the compositions require, in addition to an alcohol, a surfactant, and a volatile silicone wetting agent.
- the preferred embodiment of the present composition incorporates urea and lactic acid which collectively thin thickened nails, enhance nail hydration and diminish discoloration.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/225,980 US10543276B2 (en) | 2016-08-08 | 2018-12-19 | Topical compositions |
PCT/US2019/023203 WO2020131147A1 (en) | 2018-12-19 | 2019-03-20 | Topical compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3897604A1 true EP3897604A1 (en) | 2021-10-27 |
EP3897604A4 EP3897604A4 (en) | 2022-08-17 |
Family
ID=71102691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19898484.1A Pending EP3897604A4 (en) | 2018-12-19 | 2019-03-20 | Topical compositions |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3897604A4 (en) |
JP (1) | JP2022518357A (en) |
KR (1) | KR20210107043A (en) |
CA (1) | CA3122016A1 (en) |
IL (1) | IL284072A (en) |
MX (1) | MX2021006810A (en) |
SG (1) | SG11202105755PA (en) |
WO (1) | WO2020131147A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12090133B2 (en) | 2020-11-05 | 2024-09-17 | The Mentholatum Company | Topical composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2673537B1 (en) * | 1991-03-08 | 1993-06-11 | Oreal | USE OF HYDROPHILIC PENETRATION AGENTS IN DERMATOLOGICAL COMPOSITIONS FOR THE TREATMENT OF ONYCHOMYCOSES, AND CORRESPONDING COMPOSITIONS. |
US6585963B1 (en) * | 2001-02-15 | 2003-07-01 | Watson Pharmaceuticals, Inc. | Nail compositions and methods of administering same |
US6921529B2 (en) * | 2002-07-29 | 2005-07-26 | Joseph C. Maley | Treatment modality and method for fungal nail infection |
US8486374B2 (en) * | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US20060165747A1 (en) * | 2005-01-24 | 2006-07-27 | David Rolf | Antifungal composition, method and kit for topically treating onychomycosis |
EP2207546A1 (en) * | 2007-10-09 | 2010-07-21 | Humco Holding Group, Inc. | Antifungal treatment of nails |
CA2764236A1 (en) * | 2009-08-13 | 2011-02-17 | Moberg Derma Ab | Compositions and methods for treating fungal infection of the nail |
GB2478159A (en) * | 2010-02-26 | 2011-08-31 | Lrc Products | Composition for the treatment of fungal nail infection |
WO2014140507A1 (en) * | 2013-03-15 | 2014-09-18 | Moberg Pharma Ab | Pharmaceutical composition for the treatment of fungal infections |
US10335442B1 (en) * | 2016-08-08 | 2019-07-02 | Marlinz Pharma, LLC | Method for topical treatment of nail conditions |
-
2019
- 2019-03-20 KR KR1020217022200A patent/KR20210107043A/en active Search and Examination
- 2019-03-20 WO PCT/US2019/023203 patent/WO2020131147A1/en unknown
- 2019-03-20 SG SG11202105755PA patent/SG11202105755PA/en unknown
- 2019-03-20 MX MX2021006810A patent/MX2021006810A/en unknown
- 2019-03-20 EP EP19898484.1A patent/EP3897604A4/en active Pending
- 2019-03-20 JP JP2021536333A patent/JP2022518357A/en active Pending
- 2019-03-20 CA CA3122016A patent/CA3122016A1/en active Pending
-
2021
- 2021-06-16 IL IL284072A patent/IL284072A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL284072A (en) | 2021-08-31 |
KR20210107043A (en) | 2021-08-31 |
EP3897604A4 (en) | 2022-08-17 |
MX2021006810A (en) | 2021-07-02 |
JP2022518357A (en) | 2022-03-15 |
CA3122016A1 (en) | 2020-06-25 |
AU2019405915B2 (en) | 2025-02-06 |
SG11202105755PA (en) | 2021-07-29 |
WO2020131147A1 (en) | 2020-06-25 |
AU2019405915A1 (en) | 2021-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002246119B2 (en) | Topical composition | |
US8840911B2 (en) | Moisturizing hand sanitizer | |
CN103083196A (en) | Synergistically active ternary anti-microbial mixtures | |
AU2002246119A1 (en) | Topical composition | |
EP2498752B1 (en) | Composition for topical application, uses thereof, applicator device and kit of parts | |
KR20080080355A (en) | Pharmaceutical composition for nails | |
JP2013503123A (en) | Use of 1,3-diols as biocides | |
HUE026887T2 (en) | New pharmaceutical composition for the treatment of fungal infections | |
JP2008517037A (en) | Synergistic mixture comprising 1,2-hexanediol and 1,2-octanediol and further a preservative | |
JP2020059758A (en) | Stabilized multiple emulsions as skin protection products | |
US10543276B2 (en) | Topical compositions | |
EP3897604A1 (en) | Topical compositions | |
JP2004352688A (en) | Antiseptic agent | |
JPS6355483B2 (en) | ||
US10258560B1 (en) | Composition for topical treatment of nail conditions | |
AU2019405915B9 (en) | Topical compositions | |
CN107427006A (en) | Isobide ether derivant with antiseptic activity | |
JP2019210250A (en) | Preservative composition containing isopentyldiol | |
US9775346B1 (en) | Hand sanitizer composition and method of manufacture | |
DE69623641T2 (en) | TOPICAL FOAMING MEDICINE FOR THE TREATMENT OF SKIN DISEASES CAUSED BY PITYROSPORUM OVALE | |
JP2007501832A (en) | Topical composition containing terbinafine and hydrocortisone | |
JP2007501832A6 (en) | Topical composition containing terbinafine and hydrocortisone | |
DE102015223901A1 (en) | preparation | |
WO2023042221A1 (en) | Molecular iodine and propanediol based formulation and its application in beard care | |
US20240122891A1 (en) | Compositions with antimicrobial properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210622 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220718 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/26 20060101ALI20220712BHEP Ipc: A61K 47/18 20170101ALI20220712BHEP Ipc: A61K 47/10 20170101ALI20220712BHEP Ipc: A61K 31/454 20060101ALI20220712BHEP Ipc: A61K 31/4174 20060101ALI20220712BHEP Ipc: A61K 31/137 20060101ALI20220712BHEP Ipc: A61K 9/06 20060101ALI20220712BHEP Ipc: A61P 31/10 20060101ALI20220712BHEP Ipc: A61K 47/14 20170101ALI20220712BHEP Ipc: A61K 47/12 20060101ALI20220712BHEP Ipc: A61K 31/34 20060101ALI20220712BHEP Ipc: A61K 31/325 20060101ALI20220712BHEP Ipc: A61K 31/201 20060101ALI20220712BHEP Ipc: A61K 31/17 20060101AFI20220712BHEP |